$2.93
arrow_drop_down2.33%Key Stats | |
---|---|
Open | $3.01 |
Prev. Close | $3.00 |
EPS | -1.23 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $110.82M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 2.83 | 3.03 |
52 Week Range | 2.53 | 6.85 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.23 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotechnology Announces Details of Virtual KOL Event
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results